JB
PRQR icon

Julian Baker’s ProQR Therapeutics PRQR Stock Holding History

Julian Baker’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-212,698
Closed -$1.04M – 127
2016
Q4 		$1.04M Sell
212,698
-647,766
-75% -$3.34M 0.01% 106
2016
Q3 		$5.74M Sell
860,464
-373,631
-30% -$2.06M 0.05% 67
2016
Q2 		$5.97M Sell
1,234,095
-115,624
-9% -$595K 0.06% 66
2016
Q1 		$6.59M Buy
1,349,719
+361,420
+37% +$1.84M 0.07% 68
2015
Q4 		$8.58M Hold
988,299
– – 0.07% 65
2015
Q3 		$14.4M Hold
988,299
– – 0.13% 53
2015
Q2 		$16.5M Buy
988,299
+588,299
+147% +$11.1M 0.14% 54
2015
Q1 		$8.75M Hold
400,000
– – 0.07% 63
2014
Q4 		$8.67M Hold
400,000
– – 0.09% 53
2014
Q3 		$6.88M Buy
+400,000
New +$6.41M 0.09% 52

Other funds holding PRQR

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.72B AUM 7.92% 1-Year Est. Return

Julian Baker's PRQR Position: Q1 2017 in Review

Julian Baker sold out of ProQR Therapeutics (PRQR) in Q1 2017, closing a stake of 212,698 shares — an estimated $1.04M sold.

Julian Baker first reported a position in PRQR in Q3 2014 and held it in 10 quarters. The position peaked at $16.5M in Q2 2015. 20 funds tracked by Wall St. Rank hold PRQR as of Q1 2017.

  • Julian Baker reported no remaining ProQR Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Julian Baker sold 212,698 ProQR Therapeutics shares in Q1 2017, an estimated $1.04M.
  • Julian Baker first reported a position in ProQR Therapeutics in Q3 2014 and held it in 10 quarters.
  • Julian Baker's ProQR Therapeutics position peaked at $16.5M in Q2 2015.
  • 20 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2017.

Based on Baker Bros. Advisors's 13F filing for Q1 2017, filed 15 May 2017.